EU Clinical Trial 2018-004655-20

CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMAB IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (THE LIGHT TRIAL)  May 30, 2019

Main objective of the trial: This is a proof-of concept RCT trying to generate evidence that inhibition of IL-1α through the administration of bermekimab may inhibit progression of SSc. Πρόκειται για μια κλινική μελέτη που προσπαθεί να διερευνήσει αν η αναστολή της IL-1α μέσω της χορήγησης της μπερμεκιμάμπης μπορεί να αναστείλει την εξέλιξη της SSc.

Parties

Sponsors
Keywords
BERMEKIMAB N/A Systemic scleroderma

JSON preview

Similar records

Title

Source:  EMA Last updated:  Jun 5, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.